Preliminary verification of Bacopa monniera and network pharmacology research for the treatment of non-alcoholic fatty liver disease

Abstract

Bacoside - A, a dynamic component of Bacopa monniera is utilized in different ailments. The pharmacodynamics and cellular pathways overseeing the impacts of Bacoside- A on NAFLD stay unclear. In this study, we examined Bacoside - A pharmacology through evaluation of its chemical constituents and assessed and screened its components using drug likeness, pharmacokinetic characteristics (absorption, distribution, metabolism, excretion, and toxicity), and appropriate compensation mechanisms. We performed expectations of the dynamic BM fixings based on invert pharmacophore matching and compared different NAFLD-related genes to decide potential BM targets. Atomic docking experiments of the dynamic components were performed to uncover cellular targets. Explanation examination of both target qualities and related pathways were evaluated through the DAVID database. Cytoscape computer program was utilized to build a “component-target- path” network for the treatment of NAFLD by BM. Through data analysis, 9 active BM substances and 10 targets related to NAFLD encompassing 4 cellular pathways were identified. Data were verified through enzyme-linked immunosorbent assay and Western blot analysis. These findings provide new references for the network pharmacology of Ayurvedic medicinal compounds and NAFLD treatment.